Buy 5 Large-Cap Stocks With Extensive Robotics Applications for 2H 2026

Zacks screens five robotics-related stocks for second-half 2026 (all with Zacks Rank #2 Buy): Intuitive Surgical (ISRG), Teradyne (TER), Cadence Design Systems (CDNS), Microchip Technology (MCHP), and Fortive (FTV). The piece highlights AI-driven momentum—e.g., TER Robotics revenues up 32% YoY and rising AI-related revenue mix to 15% of quarterly sales, while CDNS raises 2026 revenue guidance to $6.125–$6.225B vs. $5.3B in 2025 and backlog stands at $8B. Overall sentiment is constructive, supported by improved consensus earnings estimates across the group, though the article flags risks like R&D uncertainty, regulation, job displacement, and data privacy.

Analysis

The cleanest beneficiary is the semiconductor-automation stack, not "robots" broadly. TER and MCHP are leveraged to the same capex cycle as AI infrastructure: if hyperscaler spend keeps pulling through, their order books can inflect faster than the end-market names because they sit closer to test, connectivity and power bottlenecks. The catch is timing: these businesses tend to look strongest 1-2 quarters before the market realizes the cycle is rolling over, so any slowdown in AI deployment or customer digestion would hit sentiment first and margins second.

CDNS is the highest-quality compounder here because complexity is structural, not cyclical; every extra node of AI, 3D-IC and packaging raises software intensity. That makes it the best long-duration winner over 6-18 months, but also the least likely to rerate dramatically on a single quarter unless backlog converts faster than expected. ISRG remains a defensive growth asset: the real upside is not procedure growth alone, but higher software/service mix and tighter hospital workflow lock-in, which can support multiple expansion if capital budgets stay open.

FTV looks like the weakest pure-play in the group because the robotics/AI narrative is more adjunct than core, so it is more exposed to the market punishing "story plus restructuring" names if revenue underdelivers. The consensus may be underestimating how narrow the true upside is: if AI capex broadens, TER/MCHP/ CDNS win; if it stays concentrated in a few hyperscalers, the benefit remains uneven and names with weaker organic growth can lag despite good product chatter. Falsifiers: a downward revision in AI-related orders, a pause in hyperscaler capex, or hospital procurement delays in ISRG's next two earnings prints.

Key Decisions for Investors

• Long TER into the next earnings cycle; best leveraged upside to AI test/automation spending. Risk/reward is attractive if Robotics keeps comping sequentially, but cut if management stops talking about acceleration in e-commerce/data-center demand.
• Long CDNS on any post-earnings volatility, with a 6-12 month horizon. This is the highest-conviction structural winner; the thesis breaks if backlog stops converting or if semiconductor design budgets flatten despite AI growth.
• Relative-value pair: long CDNS / short FTV. The pair isolates true AI/complexity exposure versus a more narrative-driven industrial turnaround; expect CDNS to outperform if the market stops rewarding generic transformation stories.
• Watchlist long MCHP only on evidence of sustained Gen6 switch/retimer traction. This is a second-order AI infrastructure beneficiary; if design wins fail to turn into revenue within 2-3 quarters, the stock can retrace hard because the market is paying for restructuring + growth.
• Hold ISRG as a quality defensive growth anchor rather than a trading vehicle. Add only if hospital capital spending stays healthy; if procedure growth slows or the multiple compresses on rates, it becomes a fade rather than a momentum name.